RE: Latest gossip20 Apr 2018 14:15
Here is what Bloomsburg is saying:
Shire rebuff may dim Takeda's appetite for a takover!
Weber�s pursuit of the mammoth acquisition reveals the challenge he faces in ensuring the future of Japan�s biggest drugmaker. With few late-stage experimental drugs in its own pipeline and a shrinking home market, Takeda needs lucrative new therapies like Shire�s medicines for rare diseases.
That could drive Weber to keep pushing for a deal even as questions swirl about his ability to pull off such a big purchase. A group of Japanese lenders, including Sumitomo Mitsui Financial Group Inc. and Mitsubishi UFJ Financial Group Inc., have agreed to arrange 1 trillion yen ($9.3 billion) in financing for the deal, according to a person familiar with the matter.The financing total may still change as Takeda�s discussions with Shire progress, according to the person, who asked not to be identified as the information is not public. Sumitomo Mitsui did not immediately respond to a request for comment on the financing arrangement. An MUFG spokesman declined to comment.
There�s a good chance Takeda could come back with another offer, and in order to make it more appealing to Shire shareholders it may have to boost the cash portion of its bid, said Credit Suisse Group analyst Fumiyoshi Sakai.